HomeInsightsStock Comparison

Alpa Laboratories Ltd vs Granules India Ltd Stock Comparison

Alpa Laboratories Ltd vs Granules India Ltd Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

  • The Latest Trading Price of Alpa Laboratories Ltd is ₹ 65.01 as of 30 Apr 15:30 . The P/E Ratio of Alpa Laboratories Ltd changed from 10.5 on March 2021 to 11.2 on March 2025 . This represents a CAGR of 1.30% over 5 yearsThe P/E Ratio of Granules India Ltd changed from 13.7 on March 2021 to 23.5 on March 2025 . This represents a CAGR of 11.40% over 5 years The Market Cap of Alpa Laboratories Ltd changed from ₹ 76.06 crore on March 2021 to ₹ 219.07 crore on March 2025 . This represents a CAGR of 23.56% over 5 yearsThe Market Cap of Granules India Ltd changed from ₹ 7511 crore on March 2021 to ₹ 11814 crore on March 2025 . This represents a CAGR of 9.48% over 5 years The revenue of Alpa Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 29.96 crore. This represent the decline of -100% The revenue of Granules India Ltd for the Mar '26 is ₹ 1495 crore as compare to the Dec '25 revenue of ₹ 1384 crore. This represent the growth of 8.02% The ebitda of Alpa Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 2.42 crore. This represent the decline of -100% The ebitda of Granules India Ltd for the Mar '26 is ₹ 376.79 crore as compare to the Dec '25 ebitda of ₹ 304.46 crore. This represent the growth of 23.76% The net profit of Alpa Laboratories Ltd changed from ₹ 5.1 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Granules India Ltd changed from ₹ 134.65 crore to ₹ 201.57 crore over 8 quarters. This represents a CAGR of 22.35% The Dividend Payout of Alpa Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Granules India Ltd changed from 6.72 % on March 2021 to 11.39 % on March 2025 . This represents a CAGR of 11.13% over 5 years .

About Alpa Laboratories Ltd

  • M/s Alpa Laboratories, formed in 1967, was incorporated as Private Limited Company as 'Alpa Laboratories Private Limited' on March 18, 1988 for manufacture of pharmaceutical formulations.
  • In 1998, the Company was converted into a Public Limited with effect from September 3, 1998.
  • The facility has manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels. In 1997, the Company initiated setting of a new manufacturing unit at Rau(Indore District), Madhya Pradesh.
  • The Unit commenced commercial production in the year 1999 of all types of formulations viz.
  • Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams. The company has manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms and market them under the trade mark 'Alpa' which is a registered trademark in the name of Alpa Labs (India) Limited, a promoter group company.

About Granules India Ltd

  • Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
  • With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
  • Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. Granules Life Sciences Private Limited, based in Hyderabad, Telangana, is a wholly owned subsidiary of Granules India.
  • It significantly enhances the Company's finished dosage manufacturing capabilities, contributing an additional 10 billion dosage units annually.

FAQs for the comparison of Alpa Laboratories Ltd and Granules India Ltd

Which company has a larger market capitalization, Alpa Laboratories Ltd or Granules India Ltd?

Market cap of Alpa Laboratories Ltd is 136 Cr while Market cap of Granules India Ltd is 17,327 Cr

What are the key factors driving the stock performance of Alpa Laboratories Ltd and Granules India Ltd?

The stock performance of Alpa Laboratories Ltd and Granules India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alpa Laboratories Ltd and Granules India Ltd?

As of May 3, 2026, the Alpa Laboratories Ltd stock price is INR ₹65.01. On the other hand, Granules India Ltd stock price is INR ₹699.25.

How do dividend payouts of Alpa Laboratories Ltd and Granules India Ltd compare?

To compare the dividend payouts of Alpa Laboratories Ltd and Granules India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions